GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athersys Inc (FRA:4LSA) » Definitions » Cyclically Adjusted PS Ratio

Athersys (FRA:4LSA) Cyclically Adjusted PS Ratio : (As of May. 30, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Athersys Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Athersys Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Athersys's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athersys Cyclically Adjusted PS Ratio Chart

Athersys Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 191.18 168.79 256.94 108.42 3.37

Athersys Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.22 3.37 - 3.30 -

Competitive Comparison of Athersys's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Athersys's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Athersys's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Athersys's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Athersys's Cyclically Adjusted PS Ratio falls into.



Athersys Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Athersys's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 is calculated as:

For example, Athersys's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0/129.8595*129.8595
=0.000

Current CPI (Sep. 2023) = 129.8595.

Athersys Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.004 98.326 0.005
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.001 100.428 0.001
201412 0.001 99.070 0.001
201503 0.001 99.621 0.001
201506 0.001 100.684 0.001
201509 0.000 100.392 0.000
201512 0.111 99.792 0.144
201603 0.162 100.470 0.209
201606 0.001 101.688 0.001
201609 0.002 101.861 0.003
201612 0.009 101.863 0.011
201703 0.012 102.862 0.015
201706 0.004 103.349 0.005
201709 0.001 104.136 0.001
201712 0.007 104.011 0.009
201803 0.005 105.290 0.006
201806 0.119 106.317 0.145
201809 0.014 106.507 0.017
201812 0.009 105.998 0.011
201903 0.009 107.251 0.011
201906 0.025 108.070 0.030
201909 -0.002 108.329 -0.002
201912 0.001 108.420 0.001
202003 0.000 108.902 0.000
202006 0.000 108.767 0.000
202009 0.000 109.815 0.000
202012 0.129 109.897 0.152
202103 0.000 111.754 0.000
202106 0.000 114.631 0.000
202109 0.444 115.734 0.498
202112 0.067 117.630 0.074
202203 0.271 121.301 0.290
202206 0.211 125.017 0.219
202209 0.006 125.227 0.006
202212 0.002 125.222 0.002
202303 0.000 127.348 0.000
202306 0.002 128.729 0.002
202309 0.000 129.860 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Athersys  (FRA:4LSA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Athersys Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Athersys's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Athersys (FRA:4LSA) Business Description

Industry
Traded in Other Exchanges
Address
3201 Carnegie Avenue, Cleveland, OH, USA, 44115-2634
Athersys Inc is a biotechnology company engaged in the field of regenerative medicine. It consists of research, clinical development, manufacturing, and manufacturing process development activities. The firm's main product is Multistem cell therapy. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants.

Athersys (FRA:4LSA) Headlines

No Headlines